Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 102Terminated 27Withdrawn 10Recruiting 8Active not recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 469Neoplasms 327Colorectal Neoplasms 236Carcinoma, Non-Small-Cell Lung 233Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 173Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 93Recurrence 88Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 78Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 69Colonic Neoplasms 68Glioblastoma 66Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 46

Interventions

peginterferon alfa-2b 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × Clear all
NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
35 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡